For the quarter ending 2026-03-31, IIPR had $41,520K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 32,809 | 31,841 | 29,305 | 57,101 |
| Depreciation and amortization | 18,584 | 18,538 | 18,639 | 36,891 |
| Impairment loss on real estate | 0 | 0 | 0 | 3,527 |
| Loss (gain) on exchange of exchangeable senior notes | - | 0 | - | - |
| Loss (gain) on sale of real estate | 422 | -326 | 0 | 0 |
| Paid-in-kind dividends and interest income on life science investments | 1,002 | 826 | - | - |
| Stock-based compensation | 2,584 | 2,698 | 2,684 | 4,750 |
| Amortization of discounts on investments | - | 0 | 0 | 0 |
| Amortization of debt discount and issuance costs | 576 | 568 | 485 | 946 |
| Other non-cash adjustments | 300 | 292 | -12 | -5 |
| Other assets, net | 527 | -1,550 | 6,555 | -3,719 |
| Accounts payable, accrued expenses and other liabilities | 3,976 | -3,607 | 1,472 | 1,281 |
| Rent received in advance and tenant security deposits | -247 | -889 | -451 | -5,529 |
| Net cash provided by (used in) operating activities | 56,031 | 49,907 | 45,591 | 102,691 |
| Investments in real estate | 0 | 0 | 0 | 7,857 |
| Investments in life science financial instruments | - | 45,016 | 105,235 | - |
| Proceeds from sale of real estate asset | 2,608 | 489 | 0 | 1,750 |
| Funding of draws for improvements and construction | 2,949 | 2,456 | 4,429 | 16,547 |
| Funding of construction loan and other investments | - | 0 | - | - |
| Purchases of short-term investments | 0 | 0 | 0 | 5,258 |
| Maturities of short-term investments | 0 | 5,258 | 0 | 5,000 |
| Net cash provided by (used in) investing activities | -341 | -41,725 | -109,664 | -22,912 |
| Principal payment on notes due 2026 | - | - | - | 8,697 |
| Issuance of common stock, net of issuance costs | 9,281 | 0 | 0 | 0 |
| Principal payment on exchangeable senior notes | - | - | - | 0 |
| Repurchase of common stock | 0 | 0 | 0 | 20,108 |
| Issuance of preferred stock, net of issuance costs | 60,301 | 5,037 | 5,900 | 13,211 |
| Draws on revolving credit facilities | 5,000 | 105,000 | 50,000 | - |
| Repayments on revolving credit facilities | 32,500 | 52,500 | - | - |
| Principal payment on debt | 0 | 0 | 8,697 | - |
| Payment of deferred financing costs | - | 0 | 0 | 0 |
| Dividends paid to common stockholders | 53,777 | 53,776 | 53,783 | 108,716 |
| Dividends paid to preferred stockholders | 1,136 | 1,017 | 878 | 1,345 |
| Taxes paid related to net share settlement of equity awards | 1,339 | 0 | 161 | 703 |
| Net cash provided by (used in) financing activities | -14,170 | 2,744 | 1,078 | -126,358 |
| Net increase (decrease) in cash and cash equivalents | 41,520 | 10,926 | -62,995 | -46,579 |
| Cash and cash equivalents, beginning of period | 47,597 | 36,671 | 146,245 | - |
| Cash and cash equivalents, end of period | 89,117 | 47,597 | 36,671 | - |
INNOVATIVE INDUSTRIAL PROPERTIES INC (IIPR)
INNOVATIVE INDUSTRIAL PROPERTIES INC (IIPR)